Vivek Jain

Title: Vivek Jain: Innovator in Pharmaceutical Compositions

Introduction

Vivek Jain is a notable inventor based in Ghaziabad, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid oral dosage forms. His work focuses on improving the formulation of Eslicarbazepine, a medication used in the treatment of epilepsy.

Latest Patents

Vivek Jain holds a patent for "Solid oral dosage forms of eslicarbazepine." This invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers, or mixtures thereof. The patent also describes a process for preparing high drug load solid oral pharmaceutical compositions that include Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The invention addresses various technical challenges associated with the formulation development of Eslicarbazepine acetate, both at the laboratory and industrial scales. The compositions prepared according to this invention exhibit desirable technical attributes, such as comparable dissolution and bioequivalence against the reference listed drug.

Career Highlights

Vivek Jain is currently employed at Jubilant Generics Limited, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in overcoming the restrictive and complex approaches previously highlighted in the prior art regarding Eslicarbazepine acetate formulation.

Collaborations

Some of his coworkers include Ravikumar Nithiyanandam and Ganesh Vinayak Gat. Their collaboration has likely contributed to the successful development of innovative pharmaceutical solutions.

Conclusion

Vivek Jain's contributions to the field of pharmaceuticals, particularly through his patent on Eslicarbazepine formulations, demonstrate his commitment to advancing medical science. His work not only addresses existing challenges but also paves the way for more effective treatments in the future.